Zacks: Brokerages Anticipate Soleno Therapeutics, Inc. (NASDAQ:SLNO) Will Announce Earnings of -$0.07 Per Share

Brokerages expect Soleno Therapeutics, Inc. (NASDAQ:SLNOGet Rating) to post earnings of ($0.07) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Soleno Therapeutics’ earnings. Soleno Therapeutics reported earnings per share of ($0.14) during the same quarter last year, which suggests a positive year-over-year growth rate of 50%. The firm is expected to report its next earnings report on Monday, January 1st.

On average, analysts expect that Soleno Therapeutics will report full-year earnings of ($0.28) per share for the current year. For the next year, analysts expect that the business will report earnings of ($0.20) per share. Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that follow Soleno Therapeutics.

Soleno Therapeutics (NASDAQ:SLNOGet Rating) last announced its quarterly earnings data on Thursday, March 31st. The company reported ($0.08) earnings per share for the quarter, meeting the consensus estimate of ($0.08).

Separately, Zacks Investment Research upgraded shares of Soleno Therapeutics from a “hold” rating to a “buy” rating and set a $0.25 target price on the stock in a report on Thursday, April 7th.

A number of institutional investors and hedge funds have recently bought and sold shares of SLNO. Renaissance Technologies LLC raised its holdings in Soleno Therapeutics by 482.7% in the fourth quarter. Renaissance Technologies LLC now owns 60,600 shares of the company’s stock worth $25,000 after purchasing an additional 50,200 shares during the period. BlackRock Inc. raised its holdings in Soleno Therapeutics by 868.8% in the third quarter. BlackRock Inc. now owns 129,773 shares of the company’s stock worth $120,000 after purchasing an additional 116,378 shares during the period. Millennium Management LLC bought a new stake in shares of Soleno Therapeutics during the second quarter worth $222,000. Two Sigma Investments LP increased its position in shares of Soleno Therapeutics by 67.6% during the third quarter. Two Sigma Investments LP now owns 365,846 shares of the company’s stock worth $338,000 after acquiring an additional 147,594 shares in the last quarter. Finally, Granite Point Capital Management L.P. increased its position in shares of Soleno Therapeutics by 20.7% during the fourth quarter. Granite Point Capital Management L.P. now owns 846,850 shares of the company’s stock worth $347,000 after acquiring an additional 145,012 shares in the last quarter. Institutional investors own 69.49% of the company’s stock.

Shares of NASDAQ SLNO opened at $0.18 on Tuesday. The company’s 50 day simple moving average is $0.23 and its 200 day simple moving average is $0.41. Soleno Therapeutics has a fifty-two week low of $0.13 and a fifty-two week high of $1.67. The firm has a market capitalization of $14.18 million, a P/E ratio of -0.51 and a beta of 0.42.

About Soleno Therapeutics (Get Rating)

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program.

Featured Articles

Get a free copy of the Zacks research report on Soleno Therapeutics (SLNO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Soleno Therapeutics (NASDAQ:SLNO)

Receive News & Ratings for Soleno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soleno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.